Cargando…

Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis

BACKGROUND: To evaluate immunotherapy against canine visceral leishmaniasis, Leishmania major antigen and heat-killed Mycobacterium vaccae (SRL172) were used as stimulators of immune defense mechanisms and the results were compared with standard chemotherapy meglumine antimoniate. METHODS: Nineteen...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamshidi, Sh, Avizeh, R, Mohebali, M, Bokaie, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3279897/
https://www.ncbi.nlm.nih.gov/pubmed/22347294
_version_ 1782223761167089664
author Jamshidi, Sh
Avizeh, R
Mohebali, M
Bokaie, S
author_facet Jamshidi, Sh
Avizeh, R
Mohebali, M
Bokaie, S
author_sort Jamshidi, Sh
collection PubMed
description BACKGROUND: To evaluate immunotherapy against canine visceral leishmaniasis, Leishmania major antigen and heat-killed Mycobacterium vaccae (SRL172) were used as stimulators of immune defense mechanisms and the results were compared with standard chemotherapy meglumine antimoniate. METHODS: Nineteen mongrel dogs aging 1-3 years old were used in this experiment. Infection was carried out in 15 out of 19 dogs using L. infantum, isolated from a naturally infected poly-symptomatic dog. RESULTS: All the cases showed positive serologic results by direct agglutination test during 30-60 days following inoculation. In the first group, which was under chemotherapy (Glucantime(R)), one of the members showed recurrence of the disease despite rapid effect of the therapeutic protocol. Immunotherapy using SRL172 caused complete cleaning of the parasite in group 2, but the speed was less than Glucantime. Immunotherapy using L. major antigen combined with M. vaccae in group 3 and combine administration of immunotherapy and chemotherapy in group 4 both were with relapsing of one case in each group. Group 5 and 6 were consisted of positive and negative control dogs, respectively. CONCLUSION: Immunotherapy seems to be an adjuvant in treatment of canine leishmaniasis but it needs more investigation for final confirmation.
format Online
Article
Text
id pubmed-3279897
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Tehran University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-32798972012-02-16 Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis Jamshidi, Sh Avizeh, R Mohebali, M Bokaie, S Iran J Parasitol Original Article BACKGROUND: To evaluate immunotherapy against canine visceral leishmaniasis, Leishmania major antigen and heat-killed Mycobacterium vaccae (SRL172) were used as stimulators of immune defense mechanisms and the results were compared with standard chemotherapy meglumine antimoniate. METHODS: Nineteen mongrel dogs aging 1-3 years old were used in this experiment. Infection was carried out in 15 out of 19 dogs using L. infantum, isolated from a naturally infected poly-symptomatic dog. RESULTS: All the cases showed positive serologic results by direct agglutination test during 30-60 days following inoculation. In the first group, which was under chemotherapy (Glucantime(R)), one of the members showed recurrence of the disease despite rapid effect of the therapeutic protocol. Immunotherapy using SRL172 caused complete cleaning of the parasite in group 2, but the speed was less than Glucantime. Immunotherapy using L. major antigen combined with M. vaccae in group 3 and combine administration of immunotherapy and chemotherapy in group 4 both were with relapsing of one case in each group. Group 5 and 6 were consisted of positive and negative control dogs, respectively. CONCLUSION: Immunotherapy seems to be an adjuvant in treatment of canine leishmaniasis but it needs more investigation for final confirmation. Tehran University of Medical Sciences 2011-08 /pmc/articles/PMC3279897/ /pubmed/22347294 Text en © 2011 Iranian Society of Parasitology & Tehran University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Original Article
Jamshidi, Sh
Avizeh, R
Mohebali, M
Bokaie, S
Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis
title Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis
title_full Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis
title_fullStr Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis
title_full_unstemmed Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis
title_short Immunotherapy Using Autoclaved L. major Antigens and M. vaccae with Meglumine Antimoniate, for the Treatment of Experimental Canine Visceral Leishmaniasis
title_sort immunotherapy using autoclaved l. major antigens and m. vaccae with meglumine antimoniate, for the treatment of experimental canine visceral leishmaniasis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3279897/
https://www.ncbi.nlm.nih.gov/pubmed/22347294
work_keys_str_mv AT jamshidish immunotherapyusingautoclavedlmajorantigensandmvaccaewithmeglumineantimoniateforthetreatmentofexperimentalcaninevisceralleishmaniasis
AT avizehr immunotherapyusingautoclavedlmajorantigensandmvaccaewithmeglumineantimoniateforthetreatmentofexperimentalcaninevisceralleishmaniasis
AT mohebalim immunotherapyusingautoclavedlmajorantigensandmvaccaewithmeglumineantimoniateforthetreatmentofexperimentalcaninevisceralleishmaniasis
AT bokaies immunotherapyusingautoclavedlmajorantigensandmvaccaewithmeglumineantimoniateforthetreatmentofexperimentalcaninevisceralleishmaniasis